Poly Medicure Limited (NSE:POLYMED)
India · Delayed Price · Currency is INR | Market Cap | 168.71B -12.1% |
| Revenue (ttm) | 21.34B +24.6% |
| Net Income | 3.18B -12.0% |
| EPS | 31.37 -11.9% |
| Shares Out | n/a |
| PE Ratio | 53.03 |
| Forward PE | 36.62 |
| Dividend | 3.50 (0.21%) |
| Ex-Dividend Date | Aug 28, 2026 |
| Volume | 60,214 |
| Open | 1,616.00 |
| Previous Close | 1,614.30 |
| Day's Range | 1,612.10 - 1,670.50 |
| 52-Week Range | 1,182.00 - 2,094.30 |
| Beta | 0.11 |
| Analysts | Buy |
| Price Target | 1,836.00 (+10.37%) |
| Earnings Date | Nov 5, 2026 |
About Poly Medicure
Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, including I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid lines over the wire, extension line, enteral connector, central venous c... [Read more]
Financial Performance
In fiscal year 2026, Poly Medicure's revenue was 18.75 billion, an increase of 12.30% compared to the previous year's 16.70 billion. Earnings were 3.22 billion, a decrease of -4.85%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for POLYMED stock is "Buy." The 12-month stock price target is ₹1,836, which is an increase of 10.37% from the latest price.
News
Poly Medicure Transcript: Q2 26/27
H1 consolidated revenue rose 31% to INR 1,106 crore, with 14% organic growth, while standalone EBITDA margins improved. FY27 revenue guidance was reaffirmed and standalone margin guidance raised; Europe rebounded, offset by West Asia logistics disruption.
Poly Medicure Quarterly report: Q2 2027
Poly Medicure has published its Q2 2027 quarterly earnings report on November 5, 2026.
Poly Medicure Slides: Q2 2027
Poly Medicure has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 5, 2026.
Poly Medicure Transcript: Q1 26/27
Q1 saw strong revenue and margin growth, with consolidated revenue up 30.3% and gross margin at 73.4%. Guidance for FY 2027 is maintained, with robust CapEx plans and continued focus on high-tech segments. Middle East logistics and Chinese pricing pressure remain key risks.
Poly Medicure Quarterly report: Q1 2027
Poly Medicure has published its Q1 2027 quarterly earnings report on August 10, 2026.
Poly Medicure Slides: Q1 2027
Poly Medicure has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 10, 2026.
Poly Medicure cancels investor meeting scheduled for 27th May 2026
Poly Medicure has announced the cancellation of an investor meeting that was scheduled for 27th May 2026. The meeting, which was to be held at the company's plant in Faridabad,…
Poly Medicure Transcript: Q4 25/26
FY 2026 saw a strategic pivot to high-tech segments, 12.3% consolidated revenue growth, and strong margin performance despite raw material and logistics headwinds. FY 2027 guidance targets 23–25% consolidated EBITDA margin and 20%+ growth in key segments.
Poly Medicure Quarterly report: Q4 2026
Poly Medicure has published its Q4 2026 quarterly earnings report on May 25, 2026.
Poly Medicure Slides: Q4 2026
Poly Medicure has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 25, 2026.
Poly Medicure Annual report: Q4 2026
Poly Medicure has published its Q4 2026 annual report on May 25, 2026.
Top losers in morning trade: gujarat state petronet at ₹268.35 down 7.13%, poly medicure at ₹1,520.00 falls 4.89%, polyplex corporation at ₹914.50 down 4.88%
The Indian stock market displayed a mixed sentiment today, with the SENSEX rising by 1.50% to 76,549.82 and the NIFTY 50 gaining 1.39% to reach 24,049.55. Despite the overall positive…
Poly Medicure Q4 Results: Net profit falls 27.8% YoY to Rs 66.3 crore, revenue rises 21.3%
Medical devices maker Poly Medicure reported a mixed set of Q4 FY26 earnings on May 25, 2026, as strong revenue growth was overshadowed by pressure on profitability and margins. Following…
Poly Medicure Slides: Investor presentation
Poly Medicure has posted slides in relation to its latest quarterly earnings report, which was published on March 7, 2026.
Poly Medicure Transcript: Q3 25/26
Q3 FY26 saw 16.4% YoY revenue growth, strong gross margins, and robust domestic and international expansion, driven by acquisitions and new product launches. Guidance for FY27 targets 20%+ consolidated revenue growth, with continued margin strength and significant CapEx for capacity expansion.
Poly Medicure Quarterly report: Q3 2026
Poly Medicure has published its Q3 2026 quarterly earnings report on February 6, 2026.
Poly Medicure Slides: Q3 2026
Poly Medicure has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 6, 2026.
Poly Medicure Transcript: Q2 25/26
Revenue grew 5.7% YoY in Q2 and 5.3% in H1, with strong domestic growth and sequential recovery in international markets. Two acquisitions are set to add INR 280 crore annual revenue, while margin guidance remains at 25%-27%. FY26 revenue growth is now guided at 15%-16%.
Poly Medicure Quarterly report: Q2 2026
Poly Medicure has published its Q2 2026 quarterly earnings report on November 10, 2025.
Poly Medicure Slides: Q2 2026
Poly Medicure has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 10, 2025.
Poly Medicure acquires Italy’s Citieffe for Rs 324 crore
Poly Medicure Ltd, one of India’s top medical device companies, has announced a major global expansion move. The company has signed a definitive agreement to acquire 100% stake in Medistream SA, which...
Poly Medicure cuts FY26 export growth guidance to 5-10% from 15-18% earlier
Poly Medicure, a leading player in the medical devices sector, has recently updated its export growth forecast for the financial year 2025-26. The company has trimmed its earlier export growth guidanc...
Poly Medicure Q1 Results: Revenue jumps 4.8% YoY to 403.21 crore, net profit up 25.8% YoY
Poly Medicure Limited posted steady growth in its consolidated earnings for the quarter ended June 30, 2025. Revenue from operations rose to ₹403.21 crore in Q1 FY26, a 4.8% increase from ₹384.78 cror...
Poly Medicure shares surge 3% as Q4 revenue rises 16.6% YoY to Rs 441 crore
Poly Medicure Ltd. witnessed a 3% surge in its share price during morning trade following the release of its robust Q4 results. The company reported impressive year-on-year growth across key financial...
Poly Medicure shares surge over 6% as Trump tariffs target Chinese medical imports; imposed 245% tariffs on syringes and needles
Shares of Poly Medicure Ltd jumped over 6% in Tuesday’s trade, rising Rs 122.40 to Rs 2,364.60, following a sharp rally triggered by escalating US-China trade tensions and renewed investor interest in...